Crown Bioscience Inc.
Crown Bioscience is a global contract research organization (CRO) specializing in oncology, immuno-oncology, hematological disorders, and drug discovery. Their mission is to empower customers to improve human health through innovative services, scientific talent, and high standards. They offer preclinical, translational, and advanced in vitro and in vivo models, including patient-derived xenograft (PDX), organoid, and 3D bone marrow niche models, to support drug discovery and development. Their platforms and services are designed to accelerate the development of new therapies, reduce reliance on animal models, and provide clinically relevant data.
Industries
Nr. of Employees
large (251-1000)
Crown Bioscience Inc.
Santa Clara, California, United States, North America
Products
Preclinical model and sample databases (PDX, xenograft, syngeneic, organoid)
Curated databases of preclinical models and available biospecimens for study selection and model matching to therapeutic programs, with searchable metadata to enable rapid model identification.
Organotypic 3D bone marrow niche models
In vitro 3D bone marrow niche models using bioactive hydrogels and stromal-endothelial networks designed for hematological malignancy screening, hematopoietic toxicity testing and evaluation of bone marrow-targeting therapies.
Mouse clinical trial datasets and model panels
Structured datasets and model panels derived from mouse clinical trials to support biomarker identification and translational analyses.
Spatial transcriptomics service (barcoded-slide whole-transcriptome)
Sequencing-based spatial gene expression mapping workflows compatible with FFPE and fresh frozen tissue, producing spatially resolved whole-transcriptome data integrated with histology.
Preclinical model and sample databases (PDX, xenograft, syngeneic, organoid)
Curated databases of preclinical models and available biospecimens for study selection and model matching to therapeutic programs, with searchable metadata to enable rapid model identification.
Organotypic 3D bone marrow niche models
In vitro 3D bone marrow niche models using bioactive hydrogels and stromal-endothelial networks designed for hematological malignancy screening, hematopoietic toxicity testing and evaluation of bone marrow-targeting therapies.
Mouse clinical trial datasets and model panels
Structured datasets and model panels derived from mouse clinical trials to support biomarker identification and translational analyses.
Spatial transcriptomics service (barcoded-slide whole-transcriptome)
Sequencing-based spatial gene expression mapping workflows compatible with FFPE and fresh frozen tissue, producing spatially resolved whole-transcriptome data integrated with histology.
Services
Preclinical in vivo model services
Design, execution and analysis of in vivo oncology studies using PDX, CDX, syngeneic, humanized and orthotopic models, including efficacy, pharmacology and safety endpoints.
In vitro and organoid assay services
Development and testing of 2D and 3D in vitro assays including organoids, tumoroids, co-cultures and high-content imaging readouts for target validation and lead selection.
3D bone marrow niche ex vivo screening services
Ex vivo drug screening and hematopoietic toxicity assessment using bioactive hydrogel-based 3D bone marrow niche models that include stromal and endothelial compartments and support patient-derived cells and immune cell co-cultures.
Biospecimen solutions and biobanking
Acquisition, processing and long-term storage of human biospecimens, including longitudinal plasma collections to support biomarker research and translational studies.
Genomics, transcriptomics and NGS data analysis
End-to-end genomics services including NGS library preparation, sequencing and computational analysis such as RNA-seq panels and cell line authentication.
Spatial transcriptomics and multiplex IHC services
Sequencing- and probe-based spatial transcriptomics workflows and multiplex immunohistochemistry combined with image analysis to map gene and protein expression in histological context for biomarker discovery and tissue-based analyses (FFPE and fresh-frozen compatible).
Preclinical in vivo model services
Design, execution and analysis of in vivo oncology studies using PDX, CDX, syngeneic, humanized and orthotopic models, including efficacy, pharmacology and safety endpoints.
In vitro and organoid assay services
Development and testing of 2D and 3D in vitro assays including organoids, tumoroids, co-cultures and high-content imaging readouts for target validation and lead selection.
3D bone marrow niche ex vivo screening services
Ex vivo drug screening and hematopoietic toxicity assessment using bioactive hydrogel-based 3D bone marrow niche models that include stromal and endothelial compartments and support patient-derived cells and immune cell co-cultures.
Biospecimen solutions and biobanking
Acquisition, processing and long-term storage of human biospecimens, including longitudinal plasma collections to support biomarker research and translational studies.
Genomics, transcriptomics and NGS data analysis
End-to-end genomics services including NGS library preparation, sequencing and computational analysis such as RNA-seq panels and cell line authentication.
Spatial transcriptomics and multiplex IHC services
Sequencing- and probe-based spatial transcriptomics workflows and multiplex immunohistochemistry combined with image analysis to map gene and protein expression in histological context for biomarker discovery and tissue-based analyses (FFPE and fresh-frozen compatible).
Expertise Areas
- Oncology and immuno-oncology preclinical research
- Preclinical model development (PDX, CDX, syngeneic, humanized, organoids)
- Hematological disease modeling and 3D bone marrow niche assays
- Biomarker discovery and translational biomarker strategy
Key Technologies
- Patient-derived xenograft (PDX) models
- Humanized genetically engineered mouse models
- Organoids and 3D culture systems
- 3D bioactive hydrogel scaffolds and pre-vascularized cultures